IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Venturi Wealth Management LLC

Venturi Wealth Management LLC boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 465.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 571 shares of the company’s stock after acquiring an additional 470 shares during the quarter. Venturi Wealth Management LLC’s holdings in IDEXX Laboratories were worth $236,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the company. D.A. Davidson & CO. increased its position in IDEXX Laboratories by 2.8% during the fourth quarter. D.A. Davidson & CO. now owns 1,674 shares of the company’s stock worth $692,000 after buying an additional 45 shares during the period. Truist Financial Corp increased its position in IDEXX Laboratories by 13.9% during the fourth quarter. Truist Financial Corp now owns 27,784 shares of the company’s stock worth $11,487,000 after buying an additional 3,382 shares during the period. CIBC Asset Management Inc increased its position in IDEXX Laboratories by 3.1% during the fourth quarter. CIBC Asset Management Inc now owns 26,366 shares of the company’s stock worth $10,901,000 after buying an additional 788 shares during the period. J.W. Cole Advisors Inc. increased its position in IDEXX Laboratories by 4.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 2,760 shares of the company’s stock worth $1,141,000 after buying an additional 118 shares during the period. Finally, Blue Zone Wealth Advisors LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $3,958,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.0 %

Shares of IDXX stock opened at $452.77 on Friday. The business’s fifty day moving average price is $431.50 and its 200 day moving average price is $452.42. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a market capitalization of $37.08 billion, a PE ratio of 42.43, a P/E/G ratio of 3.39 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Finally, Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock valued at $6,161,276 over the last quarter. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.